Intensity Therapeutics (INTS) Research & Development (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Research & Development came in at $1.2 million in Q1 2026, down 45.41% YoY from $2.2 million in Q1 2025, and down 20.44% on a QoQ basis from $1.5 million in Q4 2025.
Intensity Therapeutics (INTS) Research & Development (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Research & Development data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Research & Development fell 45.41% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 41.33% YoY) and the FY2025 annual result came in at $6.8 million, down 35.36% from the prior year.
- Research & Development retreated to $1.2 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.6 million in Q2 2024 to a low of $774000.0 in Q1 2023.
- A 5-year average of $1.7 million and a median of $1.5 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development soared 314.78% — and 2025, when it sank 56.75%.
- Tracing INTS's Research & Development over 5 years: stood at $890797.0 in 2022, then soared by 102.18% to $1.8 million in 2023, then grew by 9.22% to $2.0 million in 2024, then retreated by 23.64% to $1.5 million in 2025, then decreased by 20.44% to $1.2 million in 2026.
- The last three Research & Development figures came in at $1.2 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 3.56 Mn |
| Mar 31, 2024 | 2.82 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 859,000.00 |
| Mar 31, 2023 | 774,000.00 |
| Dec 31, 2022 | 890,797.00 |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.39 Mn |